China The Light In The Tunnel? Merck Thinks So
Market Delivers 17% Growth
As the first major country apparently emerging from the coronavirus outbreak, China offers a ray of hope for healthcare companies struggling with a large drop in prescriptions and vaccine use as the outbreak continues to wreak havoc in the US, Europe, Japan and emerging markets.
You may also be interested in...
Overall, the pharma lowered its 2020 revenue guidance by $2.5bn at the midpoint, but also says it will save about $400m on SG&A expenses. Pandemic impacts expected mainly in Q2, normal resumption in Q4.
Lilly for the first time breaks out its China business after reporting whopping 93% volume growth in Q1 and a 30% rise in constant currency terms in the first major coronavirus-stricken country.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.